Alyeska Investment Group
ABOS icon

Alyeska Investment Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Alyeska Investment Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.55M Hold
2,454,754
– – 0.02% 477
2026
Q1 		$5.78M Buy
2,454,754
+1,515,151
+161% +$3.86M 0.02% 457
2025
Q4 		$1.98M Hold
939,603
– – 0.01% 523
2025
Q3 		$1.61M Hold
939,603
– – ﹤0.01% 519
2025
Q2 		$1.09M Hold
939,603
– – ﹤0.01% 502
2025
Q1 		$1.03M Hold
939,603
– – ﹤0.01% 436
2024
Q4 		$1.62M Hold
939,603
– – 0.01% 472
2024
Q3 		$2.33M Hold
939,603
– – 0.01% 408
2024
Q2 		$2.27M Hold
939,603
– – 0.01% 402
2024
Q1 		$3.81M Buy
939,603
+206,400
+28% +$778K 0.02% 345
2023
Q4 		$2.82M Buy
733,203
+119,381
+19% +$354K 0.02% 346
2023
Q3 		$2.55M Buy
+613,822
New +$3.79M 0.02% 373

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Alyeska Investment Group's ABOS Position: Q2 2026 in Review

Alyeska Investment Group held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 2,454,754 shares worth $6.55M. The position accounts for 0.02% of the portfolio, ranked #477.

Alyeska Investment Group first reported a position in ABOS in Q3 2023 and has held it in 12 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Alyeska Investment Group held 2,454,754 shares of Acumen Pharmaceuticals worth $6.55M as of Q2 2026.
  • Alyeska Investment Group left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 0.02% of Alyeska Investment Group's portfolio in Q2 2026, its #477 holding.
  • Alyeska Investment Group first reported a position in Acumen Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.